Autologous T Cell Vaccine (TCV) for Multiple Sclerosis

Clinical trial NCT00245622 · COMPLETED

Trial details

NCT number: NCT00245622
Sponsor: Opexa Therapeutics, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsing-Remitting Multiple Sclerosis

Start date: 2006-05-01
Primary completion: 2008-09-01
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.